Systematic evaluation of cancer‐specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts

Autor: Yishuo Wu, Zhuqing Shi, Quanwa Bao, Haifei Jia, Chelsea Perschon, David Duggan, Brian T. Helfand, Xiaoling Lin, Hongjie Yu, Jianfeng Xu, Siqun L. Zheng
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Genotype
Population
Single-nucleotide polymorphism
Polymorphism
Single Nucleotide
genetic risk score
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
Genotype-phenotype distinction
Prostate
Neoplasms
Internal medicine
Cancer screening
Odds Ratio
medicine
Electronic Health Records
Humans
cancer
Genetic Predisposition to Disease
Public Health Surveillance
Radiology
Nuclear Medicine and imaging
education
Thyroid cancer
Alleles
Genetic Association Studies
Original Research
education.field_of_study
Genome
Human
business.industry
fungi
Genomics
Odds ratio
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
age at diagnosis
Female
Risk assessment
business
Cancer Prevention
Zdroj: Cancer Medicine, Vol 8, Iss 6, Pp 3196-3205 (2019)
Cancer Medicine
ISSN: 2045-7634
Popis: Background Genetic risk score (GRS) is an odds ratio (OR)‐weighted and population‐standardized method for measuring cumulative effect of multiple risk‐associated single nucleotide polymorphisms (SNPs). We hypothesize that GRS is a valid tool for risk assessment of most common cancers. Methods Utilizing genotype and phenotype data from The Cancer Genome Atlas (TCGA) and Electronic Medical Records and Genomics (eMERGE), we tested 11 cancer‐specific GRSs (bladder, breast, colorectal, glioma, lung, melanoma, ovarian, pancreatic, prostate, renal, and thyroid cancer) for association with the respective cancer type. Cancer‐specific GRSs were calculated, for the first time in these cohorts, based on previously published risk‐associated SNPs using the Caucasian subjects in these two cohorts. Results Mean cancer‐specific GRS in the population controls of eMERGE approximated the expected value of 1.00 (between 0.98 and 1.02) for all 11 types of cancer. Mean cancer‐specific GRS was consistently higher in respective cancer patients than controls for all 11 types of cancer (P 1.5, respectively), significant dose‐response associations of higher cancer‐specific GRS with higher OR of respective type of cancer were found for nine types of cancer (P‐trend
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje